ClinicalTrials.gg
RecruitingNCT07356167PNRT for mTBIUpdated Nov 17, 2026

Passive Neurosensory Reintegration Training as a Tool to Augment Mild Traumatic Brain Injury

An interventional study of Passive neurosensory reintegration training (PNRT) in Mild Traumatic Brain Injury, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Miami · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 17, 2026Enrollment updatedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 420 studies in Brain Concussion with a site in United States — 102 open to participants now, 123 under way, 5 of them phase 3. Brain Concussion · United States.

Planned enrollment
136th of 323
75 · median 60
Started
2025
with 26 others
No phase
265 of 420
63 open now
Primary completion
2026-12
later than 35 of 122 live
Registered
398th of 420
by date

Among the 420 studies in Brain Concussion with a site in United States, this one is the 136th largest by planned enrollment of the 323 interventional ones that give a count, is one of 27 that started in 2025, is one of 265 with no phase, reaches primary completion later than 35 of the 122 other live ones, and was the 398th registered.

Brain Concussion

641 studies on the registry are indexed under Brain Concussion; 167 are open to participants now.

Browse Brain Concussion studies →

Open to participants now

102 of the 420 studies in Brain Concussion with a site in United States are open now. Recruiting first, the newest first:

96 more — sign in →

All 102 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Brain Concussion studies recruiting now, 34 (30%) set no upper age limit and 73 (64%) stop at 75 or younger; 24 take children under 18; 38 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 420 studies in Brain Concussion with a site in United States, or all of them as a file.
02

Study summary

Mild traumatic brain injury (mTBI) poses a substantial clinical and public health burden, often leading to persistent neurosensory and cognitive symptoms for which diagnostic and therapeutic solutions remain limited. This study proposes a multimodal diagnostic framework that integrates established mTBI screening tools and clinical neuro-optometric assessments with high-resolution oculomotor, vestibular, and reaction time (OVRT) testing to enhance diagnostic precision and identify prognostic markers of recovery. Normative data will be established in healthy controls to inform objective thresholds and support clinical implementation. Concurrently, we will evaluate the safety, tolerability, and preliminary efficacy of a novel, minimal-risk multisensory therapeutic intervention (i.e., passive neurosensory reintegration training, or PNRT) for individuals with sub-acute or chronic mTBI. By addressing critical gaps in both diagnosis and treatment, this project will improve mTBI recovery outcomes, inform future clinical trials, and advance evidence-based mTBI care guidelines.

03

Conditions studied

  • Mild Traumatic Brain Injury

Browse trials for

Keywords

  • mTBI
  • mild traumatic brain injury
  • TBI
  • visuo-vestibular dysfunction
  • vestibular dysfunction
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 or older
  2. Clear mechanism of injury (i.e., direct or indirect impact to head), or Any individual presenting with complaints of sudden (\<24h) onset neurosensory symptoms as characterized by hearing a noise, feeling a force, or having an unexpected neurosensory perception and unexplained by any other known etiology ("sudden neurosensory events" or SNEs)
  3. Glasgow Coma Scale (GCS) score of 8 -15 at the time of injury
  4. Observed or reported focal signs at the time of injury (e.g., loss of consciousness, amnesia, or confusion) or neurosensory symptoms (e.g., dizziness, headaches, photo/phonophobia, fatigue, vision problems, sleep changes, mood changes, cognitive fog) lasting over 4 weeks to 3 months (sub-acute), or over 3 months (chronic) following brain injury

Exclusion criteria

Exclusion Criteria:

  1. Any of the following: moderate to severe TBI characterized by penetrating head trauma, GCS \<8 at the time of injury, LOC >30 minutes or PTA >24 hours, subdural or epidural hemorrhage for most recent occurence
  2. mTBI/SNE Group: History of 4 or more clinically diagnosed mTBIs that warranted emergent assessment in a hospital or emergency department setting Control Group: History of mTBI within the last 12 months or presence of mTBI-related symptoms at time of enrollment
  3. Presence of severe aphasia
  4. History of diagnosed psychiatric disorder or /rheumatologic conditions prior to brain injury

    • Autoimmune/rheumatologic conditions: including but not limited to Lyme, POTS, EDS, long COVID
    • Psychiatric disorders: including but not limited to severe depression, schizophrenia, lupus)
  5. Documented neurological disorders (e.g., epilepsy, stroke, dementia)
  6. Legally blind (characterized by a best-corrected visual acuity of 20/200 or less in the better eye or a visual field of 20 degrees or less)
  7. History of tumor of the brain or central nervous system
  8. Wards of the state or prisoners
  9. Participants must be on stable medication regimens for at least 4 weeks prior to enrollment, with no planned medication changes during the study period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Passive Neurosensory Reintegration Training (PNRT)

    Participants will receive Passive Neurosensory Reintegration Training (PNRT), a multisensory neuromodulation protocol integrating synchronized visual, vestibular, auditory, and somatosensory inputs to promote sensory reintegration and recovery of balance and oculomotor function. Each participant will complete 12 sessions over approximately two weeks (Days 1-12). Each session lasts approximately 60 minutes and involves exposure to coordinated low-intensity light, motion, and auditory stimuli in a controlled seated position. Participants will complete standardized assessments at Baseline, Day 6 (midpoint), Day 13 (post-intervention), and Day 40 (follow-up).

    Device: Passive neurosensory reintegration training (PNRT)

  • No intervention
    No Intervention - Controls

    Participants assigned to the control arm will receive no active intervention during the initial 13-day period. They will undergo the same schedule of baseline, midpoint (Day 6), post (Day 13), and follow-up (Day 40) assessments as the PNRT group.

Interventions

  • DevicePassive neurosensory reintegration training (PNRT)

    PNRT is a non-invasive, device-based system that delivers synchronized visual, vestibular, auditory, and somatosensory stimulation. The system consists of a light box and motion platform. Participants remain supine while receiving filtered halogen light at \<10 lux intensity (non-laser, non-UV) synchronized with controlled stimuli.

06

What researchers measure

Primary outcomes

  1. Change in Dizziness Handicap Inventory (DHI) Total Score

    Change in DHI total score from baseline to Day 13 following Passive Neurosensory Reintegration Training (PNRT). The mean change will be reported with 95% confidence intervals. Additionally, the proportion of participants achieving ≥18-point reduction in DHI score will be calculated as having clinically meaningful improvement.

    Time frame: Baseline to Day 13 (Post-Intervention)

Secondary outcomes

  1. Change in the Number of Abnormal I-PAS Oculomotor Metrics

    Change from baseline in the number of I-Portal Portable Assessment System (I-PAS) oculomotor metrics outside normative reference intervals derived from the healthy control group. Metrics assessed include pursuit gain, gain asymmetry, inward/outward step gain, eye correlation, and saccadic intrusions.

    Time frame: Baseline to Day 13 (Post-Intervention)

  2. Change in SCAT-6 Symptom Severity

    Change from baseline in concussion symptom severity as assessed by the Sport Concussion Assessment Tool, 6th Edition (SCAT-6). The Symptom Severity Score is calculated as the sum of 22 symptom ratings, each scored from 0 (none) to 6 (severe), for a total score ranging from 0 to 132. Higher scores indicate greater symptom burden.

    Time frame: Baseline to Day 13 (Post-Intervention)

  3. Percentage of Participants Meeting Responder Criteria

    Participants with at least one I-Portal Portable Assessment System (I-PAS) parameter outside normative reference intervals at Baseline. A responder is defined as a participant who has at least one baseline-abnormal parameter that returns to within normative reference intervals at Day 13. Reported as the percentage of participants meeting responder criteria.

    Time frame: Baseline to Day 13 (Post-Intervention)

07

Study locations

1 of 1 sites recruiting
  • University of Miami Miller School of Medicine - Don Soffer Clinical Research Building
    Miami, Florida 33136, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in publications may be made available to qualified researchers upon reasonable request, following publication of primary study results.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 249 non-industry interventional studies with no phase under Brain Concussion, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 265 studies reached it within 28 months; a quarter within 19 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 21, 2026
StartActual
Dec 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
80→75
Nov 17, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedGlasgow Coma Scale (GCS) score of 138 -15 at the time of injury
Exclusion criteria
  • EditedAny of the following: moderate to severe TBI characterized by penetrating head trauma, GCS <138 at the time of injury, LOC >30 minutes or PTA >24 hours, subdural or epidural hemorrhage for most recent occurence
  • EditedUncontrolled autoimmuneAutoimmune/rheumatologic conditions: including but not limited to Lyme, POTS, EDS, long COVID
  • RemovedActively receiving vision therapy for current mTBI-related visual-impairment
  • AddedParticipants must be on stable medication regimens for at least 4 weeks prior to enrollment, with no planned medication changes during the study period
Nov 17, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange in Dizziness Handicap Inventory (DHI) Total Score: how it is measured was reworded
Nov 17, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • AddedChange in the Number of Abnormal I-PAS Oculomotor MetricsTime frame: Baseline to Day 13 (Post-Intervention)
  • AddedChange in SCAT-6 Symptom SeverityTime frame: Baseline to Day 13 (Post-Intervention)
  • AddedPercentage of Participants Meeting Responder CriteriaTime frame: Baseline to Day 13 (Post-Intervention)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Enrollment 80→75
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedGlasgow Coma Scale (GCS) score of 138 -15 at the time of injury
    Exclusion criteria
    • EditedAny of the following: moderate to severe TBI characterized by penetrating head trauma, GCS <138 at the time of injury, LOC >30 minutes or PTA >24 hours, subdural or epidural hemorrhage for most recent occurence
    • EditedUncontrolled autoimmuneAutoimmune/rheumatologic conditions: including but not limited to Lyme, POTS, EDS, long COVID
    • RemovedActively receiving vision therapy for current mTBI-related visual-impairment
    • AddedParticipants must be on stable medication regimens for at least 4 weeks prior to enrollment, with no planned medication changes during the study period
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in Dizziness Handicap Inventory (DHI) Total Score: how it is measured was reworded
    Secondary outcomes 3 added
    What changed in the outcomes
    • AddedChange in the Number of Abnormal I-PAS Oculomotor MetricsTime frame: Baseline to Day 13 (Post-Intervention)
    • AddedChange in SCAT-6 Symptom SeverityTime frame: Baseline to Day 13 (Post-Intervention)
    • AddedPercentage of Participants Meeting Responder CriteriaTime frame: Baseline to Day 13 (Post-Intervention)
    + 3 other changes: oversight details, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07356167
Responsible party
Erin Williams (Research Assistant Professor, University of Miami) — Principal investigator
First posted
Jan 21, 2026
Start date
Dec 15, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Erin Williams, Ph.D.
Contact
erin.williams@med.miami.edu
305-243-8959
Erin Williams, Ph.D.
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion